REMS For Obesity Drugs May Need More Specifics After Qnexa Advisory Panel
Executive Summary
Providing the details of a risk management strategy would aid sponsors in their quest for a positive response to weight-loss drugs from FDA's Endocrinologic and Metabolic Drugs Advisory Committee, the panel indicated July 15 in its review of Vivus's Qnexa
You may also be interested in...
Qnexa REMS Should Deter Off-Label Use Of Components, But Not Place Undue Burden
The Endocrinologic and Metabolic Drugs Advisory Committee voted 20-2 in favor of approving the combination of phentermine and topiramate for weight loss during its second review of Vivus’ application.
Pharma News In Brief
New White House Advisory Panel On Competitiveness
Pharma News In Brief
New White House Advisory Panel On Competitiveness